A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic
agent that may be more readily tolerated than some standard therapies. Patients will be given
the new chemotherapeutic medicine once a week, by intravenous route, for three weeks,
followed by a rest week. Treatment will be repeated in four week cycles if the patient
improves on the therapy, and if there are no adverse events that require withdrawal of
medication.